Regardless of the type of control arms (placebo, active comparator, GLP-1 RAs, and sitagliptin) or the treatment dose, semaglutide was not associated with an increase in the incidence of diaabetic retinopathy (DR) (Table S3). The gene discussed is GLP1R; the disease is retinal disorder.